Enlarge image
Carla Kriwet (archive photo): Most recently at Bosch and Siemens Hausgeräte (BSH)
Photo: picture alliance / dpa
The Merck manager Belen Garijo was an exception.
Now the only female CEO in the Dax is getting female support: With Carla Kriwet, another woman is taking over the management of one of the largest listed companies in Germany – the dialysis group Fresenius Medical Care.
The 51-year-old Kriwet will follow Rice Powell on January 1, 2023, as the Bad Homburg-based company announced.
CFO Helen Giza's contract has also been extended by another five years.
She will also take on the role of Deputy CEO.
This means that the company even has dual female leadership.
Record sales achieved at BSH
Most recently, Kriwet was CEO of BSH Hausgeräte GmbH.
Before that, she held management positions at Drägerwerk and Linde, among others.
She recently surprisingly announced her departure from the Munich Bosch subsidiary BSH at the end of April "for personal reasons" after she had reported record sales of 15.6 billion euros for the past year.
She came to BSH just two years ago from the medical technology company Philips.
"I am very pleased to continue to know that our company is in the best of hands," said Powell, who has been with FMC for 25 years.
Er Powell has been the CEO of the dialysis group listed in the leading German index since January 2013.
He has been with the company since 1997 and was appointed to its board of directors in January 2004.
This year he will reach retirement age at the age of 67 and will leave the Executive Board when his contract expires at the end of December 2022.
Fresenius Medical Care hit by pandemic
Fresenius CEO Stephan Sturm, who chairs the Supervisory Board of Fresenius Medical Care Management AG, described Kriwet as "a courageous manager with a lot of experience in the healthcare sector, with clear ideas and a lot of empathy".
FMC operates around 4,100 dialysis centers for kidney patients worldwide and treats around 345,000 patients there.
At the same time, FMC is a leading supplier of products such as dialysis machines, dialyzers and related disposable accessories.
However, Kriwet takes over FMC in difficult times.
In the first quarter of 2022, the dialysis provider's profit collapsed by almost 40 percent - again due to high costs and the excess mortality of its patients.
This also overshadowed the start of the year for the parent company Fresenius.
In addition to the pandemic, the war in Ukraine, bottlenecks in the supply chains and, in some cases, significantly increased expenses also had a negative impact on the quarter, Fresenius announced on Wednesday in Bad Homburg.
Overall, thanks to improvements at the infusion subsidiary Kabi and in the clinic business, the group reported an eight percent increase in sales for the quarter compared to the previous year to around 9.7 billion euros.
However, the operating result (EBIT) adjusted for special effects fell by one percent to 996 million euros.
The bottom line is that Fresenius was able to compensate for the decline, with adjusted net income increasing by six percent to EUR 462 million.
Apr/dpa/Reuters